SCHEMBL3783809

SCHEMBL3783809

O=C1N(c2ccccc2)CCCN1c1ncc(Cl)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
HRH3 Q9Y5N1 1/20 0.40
GRIN1 Q05586 1/20 0.39
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
MAT2A P31153 1/20 0.36
ALB P02768 1/20 0.36
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
HTR2C P28335 1/20 0.35
CYP3A4 P08684 1/20 0.35
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11114584 0.78 MEN1 (0.62) KMT2AMEN1NPC1RAB9AHRH3
SCHEMBL6362002 0.75 NPC1 (0.82) KMT2AMEN1NPC1RAB9AHRH3
SCHEMBL610584 0.68 NPC1 (1.00) KMT2AMEN1NPC1RAB9ADRD2
SCHEMBL11619888 0.67 KMT2A (0.49) KMT2AMEN1NPC1ALDH1A1HTT
SCHEMBL6362778 0.65 MEN1 (0.61) KMT2AMEN1NPC1RAB9AHRH3
SCHEMBL909200 0.65 MEN1 (0.61) KMT2AMEN1NPC1RAB9AHRH3
SCHEMBL17543471 0.64 NPC1 (0.43) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL11745206 0.64 NPC1 (0.72) KMT2AMEN1NPC1RAB9ADRD2
SCHEMBL3075186 0.63 CNR2 (0.47) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL10965901 0.63 DRD2 (0.57) KMT2AMEN1NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331326-A1 Inhibitors of CYP 17 NOVARTIS AG 2010-12-30 US claimed
US-RE45173-E1 Inhibitors of CYP 17 NOVARTIS AG (CH) 2014-09-30 US disclosed
US-20140228394-A1 INHIBITORS OF CYP 17 NOVARTIS AG (CH) 2014-08-14 US disclosed
US-8263635-B2 Inhibitors of CYP 17 NOVARTIS AG (CH) 2012-09-11 US disclosed
US-20100331326-A1 Inhibitors of CYP 17 NOVARTIS AG 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331326-A1 Inhibitors of CYP 17 CYP17A1, CYP21A2, CYP4A22 KMT2A 2512/4885MEN1 2911/4885NPC1 701/4885
US-20140228394-A1 INHIBITORS OF CYP 17 CYP17A1, CYP21A2, CYP4A22 KMT2A 2512/4885MEN1 2911/4885NPC1 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.